Literature DB >> 6884702

Intracellular distribution of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in blood cells.

T Ueda, T Nakamura, D Kagawa, K Yamamoto, M Uchida, M Sasada, H Uchino.   

Abstract

In order to clarify differences in mode of action between N4-behenoyl-1-beta-D-arabinofuranosylcytosine (behenoyl-ara-C) and 1-beta-D-arabinofuranosylcytosine (ara-C), comparative studies on both agents were undertaken. When human erythrocytes incubated with behenoyl-ara-C[acyl-1-14C] were fractionated into stroma and stroma-free lysate, a marked accumulation of radioactivity in stroma was observed. In contrast, ara-C[cytosine-2-14C] was rapidly incorporated into the stroma-free lysate. Thin-layer chromatography of the extracts of L1210 cells incubated with behenoyl-ara-C[acyl-1-14C] or behenoyl-ara-C[cytosine-2-14C] at 37 degrees for 60 min revealed that most of the incorporated drug remained as unmetabolized behenoyl-ara-C. After incubation of 20 microM behenoyl-ara-C or ara-C with L1210 cells at 37 degrees for 60 min, subcellular fractionation of the cell suspension was performed; behenoyl-ara-C was accumulated markedly in the membrane, mitochondria and microsome fractions. In contrast, most of the ara-C was found in the 105,000g supernatant fraction. The accumulation of behenoyl-ara-C in membrane structures may result from the lipophilic nature of the agent, which may have a prolonged inhibitory action on leukemic cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6884702

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  7 in total

1.  A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.

Authors:  T Fukushima; T Yamashita; N Goto; T Ueda; K I Okabe; Y Kuraishi; R Ohno; A Urabe; M Ogawa
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

2.  Incorporation of N4-behenoyl-1-beta-D-arabinofuranosylcytosine into DNA as 1-beta-D-arabinofuranosylcytosine.

Authors:  M Higashigawa; H Ochiai; T Ohkubo; H Kawasaki; T Nobori; H Kamiya; M Sakurai
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

3.  Phase I clinical and pharmacokinetic study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.

Authors:  K Kimura; R Ohno; I Amaki; K Hattori; Y Hirota; A Hoshino; M Ichimaru; M Ito; I Kimura; T Maekawa
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

4.  Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.

Authors:  T Ueda; T Nakamura; D Kagawa; M Uchida; N Domae; M Sugiyama; Y Ueda; M Sasada; H Uchino
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

6.  Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line.

Authors:  Y Urasaki; T Ueda; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1994-06

7.  DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells.

Authors:  A Yoshida; T Ueda; Y Wano; T Nakamura
Journal:  Jpn J Cancer Res       Date:  1993-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.